Page 73 - Read Online

Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT 2009;27:3778-85.
gene silencing and benefit from temozolomide in glioblastoma. N 23. Gertler SZ, MacDonald D, Goodyear M, Forsyth P, Stewart DJ,
Engl J Med 2005;352:997-1003. Belanger K, Perry J, Fulton D, Steward W, Wainman N, Seymour L.
7. van Nifterik KA, van den Berg J, Stalpers LJ, Lafleur MV, Leenstra NCIC-CTG phase II study of gemcitabine in patients with malignant
S, Slotman BJ, Hulsebos TJ, Sminia P. Differential radiosensitizing glioma. (IND.94). Ann Oncol 2000;11:315-8.
potential of temozolomide in MGMT promoter methylated 24. Weller M, Streffer J, Wick W, Kortmann RD, Heiss E, Küker W,
glioblastoma multiforme cell lines. Int J Radiat Oncol Biol Phys Meyermann R, Dichgans J, Bamberg M. Preirradiation gemcitabine
2007;69:1246-53. chemotherapy for newly diagnosed glioblastoma. A phase II study.
8. Shewach DS, Lawrence TS. Gemcitabine and radiosensitization in Cancer 2001;91:423-7.
human tumor cells. Invest New Drugs 1996;14:257-63. 25. Ostruszka LJ, Shewach DS. The role of cell cycle progression in
9. Shewach DS, Lawrence TS. Nucleoside radiosensitizers. In: radiosensitization by 2’,2’-difluoro-2’-deoxycytidine. Cancer Res
Cancer drug discovery and development entitled Deoxynucleoside 2000;60:6080-8.
analogues in cancer therapy, edited by GJ Peters, Humana press, 26. Genç M, Castro Kreder N, Barten-van Rijbroek A, Stalpers LJ,
2006, p. 289-330 [chapter 13]. Haveman J. Enhancement of effects of irradiation by gemcitabine
10. Shewach DS, Lawrence TS. Antimetabolite radiosensitizers. J Clin in a glioblastoma cell line and cell line spheroids. J Cancer Res Clin
Oncol 2007;25:4043-50. Oncol 2004;130:45-51.
11. Pastor-Anglada M, Cano-Soldado P, Errasti-Murugarren E, Casado 27. Fehlauer F, Muench M, Smid EJ, Slotman B, Richter E, Van der
FJ. SLC28 genes and concentrative nucleoside transporter (CNT) Valk P, Sminia P. Combined modality therapy of gemcitabine and
proteins. Xenobiotica 2008;38:972-94. irradiation on human glioma spheroids derived from cell lines and
12. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the biopsy tissue. Oncol Rep 2006;15:97-105.
cellular pharmacokinetics and toxicity of 2’,2’-difluorodeoxycytidine 28. Galbán S, Lemasson B, Williams TM, Li F, Heist KA, Johnson TD,
and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1988;48:4024- Leopold JS, Chenevert TL, Lawrence TS, Rehemtulla A, Mikkelsen
31. T, Holland EC, Galbán CJ, Ross BD. DW-MRI as a biomarker
13. Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to compare therapeutic outcomes in radiotherapy regimens
to 2’,2’-difluorodeoxycytidine (gemcitabine). Drug Resist Updat incorporating temozolomide or gemcitabine in glioblastoma. PLoS
2002;5:19-33. One 2012;7:e35857.
14. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular 29. Sigmond J, Honeywell RJ, Postma TJ, Dirven CM, de Lange SM,
pharmacology of gemcitabine. Ann Oncol 2006;17 Suppl 5:v7-12. van der Born K, Laan AC, Baayen JC, Van Groeningen CJ, Bergman
15. Elnaggar M, Giovannetti E, Peters GJ. Molecular targets of AM, Giaccone G, Peters GJ. Gemcitabine uptake in glioblastoma
gemcitabine action: rationale for development of novel drugs and multiforme: potential as a radiosensitizer. Ann Oncol 2009;20:182-
drug combinations. Curr Pharm Des 2012;18:2811-29. 7.
16. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth 30. Metro G, Fabi A, Mirri MA, Vidiri A, Pace A, Carosi M, Russillo
J, Hochster H, Lenzi R, Abbruzzese J. Randomized phase II M, Maschio M, Giannarelli D, Pellegrini D, Pompili A, Cognetti
comparison of dose-intense gemcitabine: thirty-minute infusion and F, Carapella CM. Phase II study of fixed dose rate gemcitabine
fixed dose rate infusion in patients with pancreatic adenocarcinoma. as radiosensitizer for newly diagnosed glioblastoma multiforme.
J Clin Oncol 2003;21:3402-8. Cancer Chemother Pharmacol 2010;65:391-7.
17. Peters GJ, Clavel M, Noordhuis P, Geyssen GJ, Laan AC, Guastalla 31. Kim MM, Schipper M, Cao Y, Junck L, Marnmoser A, Heth J,
J, Edzes HT, Vermorken JB. Clinical phase I and pharmacology Sagher O, Lawrence TS, Tsien C. A phase I dose-escalation study
study of gemcitabine (2’, 2’-difluorodeoxycytidine) administered in of gemcitabine plus standard radiation therapy for malignant high
a two-weekly schedule. J Chemother 2007;19:212-21. grade gliomas. Int J Radiat Oncol Biol Phys 2014;90:S282.
18. Vernejoul F, Ghénassia L, Souque A, Lulka H, Drocourt D, Cordelier 32. Common Terminology Criteria for Adverse Events v3.0 (CTCAE).
P, Pradayrol L, Pyronnet S, Buscail L, Tiraby G. Gene therapy based Available at: http://ctep.cancer.gov (Last Accessed 1 July 2009).
on gemcitabine chemosensitization suppresses pancreatic tumor 33. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response
growth. Mol Ther 2006;14:758-67. criteria for phase II studies of supratentorial malignant glioma. J
19. Ruiz van Haperen VW, Veerman G, Boven E, Noordhuis P, Clin Oncol 1990;8:1277-80.
Vermorken JB, Peters GJ. Schedule dependence of sensitivity 34. Beauchesne PD, Taillandier L, Bernier V, Carnin C. Concurrent
to 2’,2’-difluorodeoxycytidine (Gemcitabine) in relation to radiotherapy: fotemustine combination for newly diagnosed
accumulation and retention of its triphosphate in solid tumour cell malignant glioma patients, a phase II study. Cancer Chemother
lines and solid tumours. Biochem Pharmacol 1994;48:1327-39. Pharmacol 2009;64:171-5.
20. Veerman G, Ruiz van Haperen VWT, Vermorken JB, Noordhuis 35. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis
P, Braakhuis BJM, Pinedo HM, Peters GJ. Antitumor activity M, Verigos C, Misailidou D, Antonadou D, Saris G, Beroukas K,
of prolonged as compared with bolus administration of Karageorgis P. Randomized phase II study of temozolomide and
2’,2’-difluorodeoxycytidine in vivo against murine colon tumors. radiotherapy compared with radiotherapy alone in newly diagnosed
Cancer Chemother Pharmacol 1996;38:335-42. glioblastoma multiforme. J Clin Oncol 2005;23:2372-7.
21. Abbruzzese JL. New applications of gemcitabine and future 36. Rekers NH, Sminia P, Peters GJ. Towards tailored therapy of
directions in the management of pancreatic cancer. Cancer glioblastoma multiforme. J Chemother 2011;23:187-99.
2002;95:941-5. 37. Peters GJ, Veerkamp JH. Pyrimidine metabolism in rat brain cortex
22. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, and liver. Adv Exp Med Biol 1984;165:531-4.
Alberts S, O’Dwyer P, Haller D, Catalano P, Cella D, Benson AB 3rd. 38. van Putten JWG, Groen HJM, Smid K, Peters GJ, Kampinga
Phase III, randomized study of gemcitabine and oxaliplatin versus HH. End-joining deficiency and radiosensitization induced by
gemcitabine (fixed-dose rate infusion) compared with gemcitabine gemcitabine. Cancer Res 2001;61:1585-91.
(30-minute infusion) in patients with pancreatic carcinoma E6201: 39. Pauwels B, Korst AE, Lardon F, Vermorken JB. Combined modality
a trial of the Eastern Cooperative Oncology Group. J Clin Oncol therapy of gemcitabine and radiation. Oncologist 2005;10:34-51.

Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ May 18, 2016 ¦ 193